|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00150995 |
|
Date of registration:
|
06/09/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Tetrathiomolybdate in Hormone Refractory Prostate Cancer
|
|
Scientific title:
|
A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer |
|
Date of first enrolment:
|
May 2001 |
|
Target sample size:
|
37 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00150995 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
David C. Smith, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
The University of Michigan Comprehensive Cancer Center |
| | |
|
Key inclusion & exclusion criteria
|
Patients must have histologic diagnosis of adenocarcinoma of the prostate with progression
following hormonal therapy and antiandrogen withdrawal.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Prostate Cancer
|
|
Intervention(s)
|
|
Drug: tetrathiomolybdate
|
|
Primary Outcome(s)
|
|
To determine the time to progression and pattern of progression of prostate cancer in patients with androgen-independent prostate cancer treated with tetrathiomolybdate.
|
|
Secondary ID(s)
|
|
UMCC 9962
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|